Share

Doximity Inc (DOCS.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+64.0%

DOCS.NYSE does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is arithmetical, not narrative: a cash machine retiring roughly 8% of itself annually versus an attention franchise being rented out from under it for free. The base case resolves it in favour of arithmetic, but only modestly. Revenue grinds at mid-single digits as OpenEvidence caps pricing power, while AI spend crests and adjusted EBITDA margin recovers toward the high forties. The physician graph holds because verified reach and brand safety are what pharma actually buys. Investors earn compounding ownership of a maturing franchise, not a growth re-rating.

FY2027 guidance of USD 671-681m revenue and USD 309-329m implies roughly 13.5x EV/EBITDA.
A 6% free-cash-flow yield plus 8% share retirement compounds per-share value near 10% annually at a flat multiple.
Cross-check: USD 43 by 2031 requires about 16x on modestly higher earnings — no heroic re-rating.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-16	95.5
Observed price	2021-10-02	77.9
Observed price	2021-10-14	75.6
Observed price	2021-10-22	64.8
Observed price	2021-11-11	76.7
Observed price	2021-11-23	57.1
Observed price	2021-12-01	64.8
Observed price	2021-12-17	50.1
Observed price	2021-12-25	52.0
Observed price	2022-01-06	46.9
Observed price	2022-01-14	46.0
Observed price	2022-01-26	42.5
Observed price	2022-02-07	48.5
Observed price	2022-02-27	60.6
Observed price	2022-03-03	56.8
Observed price	2022-03-15	43.2
Observed price	2022-04-04	54.0
Observed price	2022-04-12	48.7
Observed price	2022-04-20	50.0
Observed price	2022-05-10	31.3
Observed price	2022-05-18	30.3
Observed price	2022-06-03	38.0
Observed price	2022-06-11	33.6
Observed price	2022-06-27	40.4
Observed price	2022-07-01	36.7
Observed price	2022-07-21	46.2
Observed price	2022-08-02	43.8
Observed price	2022-08-14	37.3
Observed price	2022-08-18	34.3
Observed price	2022-09-03	32.6
Observed price	2022-09-11	34.0
Observed price	2022-09-27	30.2
Observed price	2022-10-05	31.7
Observed price	2022-10-21	25.0
Observed price	2022-11-06	24.3
Observed price	2022-11-18	31.7
Observed price	2022-11-22	31.5
Observed price	2022-12-08	35.8
Observed price	2022-12-16	35.1
Observed price	2023-01-05	32.0
Observed price	2023-01-09	30.6
Observed price	2023-01-29	34.5
Observed price	2023-02-02	39.7
Observed price	2023-02-10	31.7
Observed price	2023-03-06	34.1
Observed price	2023-03-10	29.1
Observed price	2023-03-30	31.2
Observed price	2023-04-11	35.2
Observed price	2023-04-23	36.4
Observed price	2023-05-05	34.1
Observed price	2023-05-13	33.4
Observed price	2023-05-29	30.6
Observed price	2023-06-06	34.1
Observed price	2023-06-10	32.0
Observed price	2023-06-26	31.9
Observed price	2023-07-16	35.5
Observed price	2023-07-28	35.5
Observed price	2023-08-09	25.3
Observed price	2023-08-17	22.1
Observed price	2023-09-02	24.3
Observed price	2023-09-06	24.1
Observed price	2023-09-26	19.86
Observed price	2023-09-30	21.2
Observed price	2023-10-16	22.2
Observed price	2023-11-01	20.3
Observed price	2023-11-13	23.9
Observed price	2023-11-17	24.6
Observed price	2023-11-29	23.9
Observed price	2023-12-11	24.0
Observed price	2023-12-31	28.3
Observed price	2024-01-04	28.0
Observed price	2024-01-20	30.9
Observed price	2024-02-05	27.3
Observed price	2024-02-17	30.1
Observed price	2024-02-21	29.0
Observed price	2024-03-12	27.7
Observed price	2024-03-20	28.5
Observed price	2024-04-05	25.8
Observed price	2024-04-09	26.4
Observed price	2024-04-25	23.6
Observed price	2024-05-11	23.2
Observed price	2024-05-19	28.7
Observed price	2024-06-04	27.7
Observed price	2024-06-12	29.6
Observed price	2024-06-28	28.0
Observed price	2024-07-10	26.6
Observed price	2024-07-22	28.8
Observed price	2024-08-03	26.7
Observed price	2024-08-07	25.5
Observed price	2024-08-27	36.7
Observed price	2024-09-04	36.2
Observed price	2024-09-20	40.9
Observed price	2024-09-24	41.4
Observed price	2024-10-02	43.5
Observed price	2024-10-18	43.5
Observed price	2024-10-26	41.3
Observed price	2024-11-11	61.3
Observed price	2024-11-23	48.4
Observed price	2024-12-13	52.1
Observed price	2024-12-25	58.3
Observed price	2025-01-06	55.6
Observed price	2025-01-14	50.8
Observed price	2025-01-26	55.8
Observed price	2025-02-07	79.2
Observed price	2025-02-15	77.3
Observed price	2025-03-07	64.0
Observed price	2025-03-23	65.2
Observed price	2025-03-31	58.0
Observed price	2025-04-08	50.7
Observed price	2025-04-24	56.3
Observed price	2025-05-10	59.8
Observed price	2025-05-18	53.4
Observed price	2025-05-22	51.3
Observed price	2025-06-07	58.6
Observed price	2025-06-15	55.9
Observed price	2025-07-05	61.3
Observed price	2025-07-09	63.3
Observed price	2025-07-29	59.7
Observed price	2025-08-02	57.7
Observed price	2025-08-22	67.7
Observed price	2025-08-26	67.1
Observed price	2025-09-15	72.5
Observed price	2025-09-27	74.6
Observed price	2025-10-01	70.6
Observed price	2025-10-21	67.9
Observed price	2025-11-02	66.6
Observed price	2025-11-06	62.6
Observed price	2025-11-18	47.4
Observed price	2025-12-04	51.3
Observed price	2025-12-16	43.8
Observed price	2026-01-05	45.7
Observed price	2026-01-13	41.4
Observed price	2026-01-17	41.2
Observed price	2026-02-06	27.7
Observed price	2026-02-10	27.2
Observed price	2026-02-22	24.4
Observed price	2026-03-06	25.3
Observed price	2026-03-26	24.3
Observed price	2026-04-11	21.6
Observed price	2026-04-19	24.5
Observed price	2026-04-23	23.2
Observed price	2026-05-09	26.1
Observed price	2026-05-17	19.38
Observed price	2026-06-02	21.5
Observed price	2026-06-22	20.1
Observed price	2026-06-26	20.9
Observed price	2026-07-04	22.4
Observed price	2026-07-24	20.4
Observed price	2026-08-01	21.2
Observed price	2026-08-13	26.6
Observed price	2026-08-29	26.7
Observed price	2026-09-10	24.7
Observed price	2026-09-21	26.8
Observed price	2026-09-24	26.0
Observed price	2026-09-25	26.4
Published advisor forecast	2026-09-18	26.1
Published advisor forecast	2026-12-18	25.3
Published advisor forecast	2027-03-18	26.8
Published advisor forecast	2027-06-18	26.3
Published advisor forecast	2027-09-18	28.2
Published advisor forecast	2027-12-18	29.6
Published advisor forecast	2028-03-18	30.7
Published advisor forecast	2028-06-18	29.5
Published advisor forecast	2028-09-18	31.3
Published advisor forecast	2028-12-18	32.5
Published advisor forecast	2029-03-18	33.5
Published advisor forecast	2029-06-18	34.5
Published advisor forecast	2029-09-18	35.9
Published advisor forecast	2029-12-18	37.0
Published advisor forecast	2030-03-18	37.7
Published advisor forecast	2030-06-18	36.6
Published advisor forecast	2030-09-18	38.4
Published advisor forecast	2030-12-18	39.6
Published advisor forecast	2031-03-18	40.4
Published advisor forecast	2031-06-18	41.6
Published advisor forecast	2031-09-18	42.8

2. Scenarios & Signals

Bull case

The bull case activates when Doximity proves the AI spend bought inventory, not merely parity. Monetized AI Search at point-of-care CPMs re-accelerates revenue to double digits just as enacted DTC restrictions push consumer budgets into the compliant professional channel. Margin recovery then compounds with a shrinking float, and the terminal-decay discount the market applies today inverts into a growth multiple. That combination — monetization plus regulatory reallocation — would justify a materially higher share price than the base path.

Bear case

The bear case activates when deceleration crosses into contraction. Free clinician tools from OpenEvidence and general-purpose labs capture the high-intent impression, pharma reallocates spend to the cheaper channel, and Doximity must defend by spending more on AI whose inference costs already sit in cost of revenue. Gross margin compresses while revenue flattens, buybacks shrink as cash is preserved, and the market reprices from maturity to decay. At that point even a 6% cash yield fails to support the shares.

Current crowd narrative

The settled belief is that Doximity is a melting ice cube: a free, venture-subsidised rival captured the point-of-care moment, so 5% growth is the ceiling and margins only compress from here. Sell-side downgrades explicitly frame AI as the cheaper substitute [7]. Anchoring runs off the USD 76.51 high and the USD 17.15 low, leaving USD 26 treated as fair value for terminal stagnation.

Alpha-gap assessment

The crowd underestimates these shares. At roughly 13.5x guided FY2027 EV/, with USD 688m of cash and securities and an 8% net buyback yield, the price embeds approximately zero long-run growth and margin erosion. Two pieces of evidence are being ignored: the GAAP earnings collapse is a discretionary R&D and stock-compensation decision, not revenue impairment [4], and the DTC crackdown reallocates promotional budget toward compliant physician channels rather than shrinking it [21][24]. The offset, genuine and priced-in only partly, is terminal-value erosion.

Convergence catalyst

The early-November 2026 Q2 FY2027 print is the first test: guidance of USD 170-171m sets a low bar the company beat by USD 5m last quarter. The observable repricing signal is GAAP stabilizing above 85% while R&D growth decelerates below revenue growth.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: high_erratic
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Retiring THE Float AT A SIX Percent YIEL	The decisive per-share mechanism: trailing net buyback yield is 8.03% against a 6.00% TTM free-cash-flow yield, with USD 400.9m still authorized at 30 June 2026 [13]. FY2026 repurchases reached USD 432m versus USD 317m of free cash flow, meaning management deliberately shrank the equity base using balance-sheet cash. At a mid-teens EBITDA multiple, every retired share compounds owner earnings faster than revenue grows, and that persists while the multiple stays depressed.	Not available	+30.0%
Pharma Dollars FLEE THE Television Scree	The federal DTC advertising crackdown targets the consumer channel, not the professional one [21][22][23]. With IQVIA showing consumer spend per patient start rising from roughly USD 2,700 to nearly USD 13,000 between 2018 and 2022 launches [25], the roughly USD 14bn promotional pool is being reallocated toward verified, compliant, physician-targeted inventory [24]. Doximity owns exactly that asset. Budget reallocation, not contraction, is the correct reading of the demand pool.	Not available	+15.0%
THE Investment YEAR LAPS Itself	The GAAP earnings collapse is a spend decision, not a revenue event. Q1 FY2027 R&D rose 43.6% YoY against 7% revenue growth, and stock-based compensation hit 23% of revenue, approximately 19% excluding a fiscal-2026 AI grant [4]. Adjusted EBITDA margin nonetheless held at 47.7% [2]. Once the AI build laps and inference cost per query falls with model efficiency, incremental margin snaps back toward the historic high-forties FCF margin.	Not available	+14.0%
Eighty FIVE Percent OF Doctors Already R	Distribution is the moat that survives model commoditization: over 80% of US physicians are registered members, with 3m+ verified accounts across the network [18][19]. Dialer, scheduling, credentialing and CME create workflow switching costs a free evidence tool cannot replicate, and Q1 FY2027 workflow active prescriber growth exceeded 30% YoY [5]. Advertisers pay for verified reach and brand safety; that verified graph is expensive to rebuild and persists through the AI transition.	Not available	+12.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
A FREE Rival Renting THE SAME Attention	OpenEvidence raised USD 250m in January 2026 at a USD 12bn valuation, gives the product away free to verified clinicians, and monetizes pharma inventory at CPMs reported between USD 70 and USD 1,000+ [14][15]. It reportedly reaches over 40% of US physicians and launched a Dialer competitor aimed squarely at Doximity's retention hook [16][20]. Venture subsidy means the rival can price at zero indefinitely; that caps Doximity's pricing power and terminal growth.	Not available	-25.0%
FIVE Percent IS THE NEW Twenty	Growth halved from 23% YoY to roughly 5%, with FY2027 guided at USD 671-681m, a 4.8% midpoint increase [5][7]. The mechanism is substitution of intent: AI search answers the clinical question before the newsfeed module is ever scrolled, so the highest-value impression migrates away from Doximity's legacy ad unit. KeyBanc downgraded precisely because budget managers now treat AI as a lower-cost channel [7]. Deceleration is the multiple's anchor.	Not available	-14.0%
Discount RATE AT FIVE Percent	The US 10-year closed at 4.998% on 18 September 2026 and the Fed raised to 3.75%-4.00% with a further hike embedded in the September median dot. For a debt-free mid-cap whose value sits in terminal cash flows beyond year five, every 50bp of real rate compresses the justified multiple materially. Doximity carries no financing cost, so the damage is purely valuation, and it persists until disinflation is credible.	Not available	-10.0%
Stock COMP EATS THE Buyback	Repurchases look heroic until you net off issuance: stock-based compensation ran at 23% of revenue in Q1 FY2027, roughly USD 37m in a single quarter [4]. A meaningful slice of the USD 432m FY2026 buyback simply offset dilution rather than concentrating ownership. Combined with dual-class Class A structure and founder control, minority holders bear the leakage without governance leverage. This is a structural, recurring drag on per-share economics.	Not available	-9.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
AI Search Learns TO BILL	Doximity monetizes its point-of-care AI surface at rival CPMs. The trigger would be a FY2028 or FY2029 disclosure quantifying sponsored clinical-answer inventory, following Q1 FY2027's reported 25%+ QoQ AI Search query growth and a growing AI commercial pipeline [3][5]. Point-of-care intent commands multiples of newsfeed pricing; even modest capture would re-accelerate revenue to double digits and validate the AI spend as investment rather than defence. Probability stays below 50% because no unit economics for AI Search monetization have been disclosed, and the rival owns the habit. Expect evidence between late 2027 and 2029.	35.0%	+45.0%
Washington Closes THE Television Channel	An enacted FDA rule restoring pre-1997 disclosure requirements would make consumer television advertising effectively impractical, forcing a multi-billion-dollar reallocation of promotional budget [22]. The Presidential Memorandum instructing HHS and FDA to revisit DTC rules is already issued; the gap is rulemaking and litigation, which is why this stays below 50% through the horizon. If it lands, verified physician-targeted digital inventory becomes the scarce compliant channel, lifting both Doximity's volume and price per impression, and re-rating a stock currently priced for stagnation. Most plausible window: 2028-2030.	28.0%	+32.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Share LOSS Turns INTO Revenue Decline	Growth crosses from deceleration into contraction as OpenEvidence enterprise deployments, following the Cedars-Sinai rollout, and free clinician tools from general-purpose labs capture the pharma impression at the point of care [16][17]. The trigger would be a FY2029 guide implying flat-to-negative revenue while adjusted EBITDA margin slips below 40%. Cash generation would still be positive, but the market would price terminal decay rather than maturity, halving the multiple. Below 50% because the verified physician graph and workflow lock-in remain intact; watch 2028-2029 guidance.	30.0%	-40.0%
Washington Taxes THE Promotion Budget	Reported plans to address advertising tax deductibility for pharmaceutical promotion would hit every channel indiscriminately, including the professional inventory that is Doximity's entire franchise [26]. Unlike the DTC crackdown, this is not reallocation but pool shrinkage: a deduction repeal raises the effective after-tax cost of every impression. Doximity, with roughly 80% of revenue from advertising [15], has no offsetting channel. Probability stays modest because enactment requires legislation rather than rulemaking, and industry lobbying is formidable. Realistic window: any budget reconciliation cycle through 2030.	18.0%	-26.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_45c1e223-6119-5011-bb1e-35aed5d58e7d__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-3.0%	25.33	The early-November Q2 print lands against a guide of only USD 170-171m, roughly 1% YoY. Even a beat leaves headline optics weak, while a 5% ten-year yield compresses mid-cap healthcare technology multiples.
2	March 18, 2027	+6.0%	26.85	December-quarter seasonality delivers Doximity's strongest revenue period as pharma sets 2027 promotional budgets. Continued repurchases absorb roughly 2% of float per quarter, tightening supply into a lightly positioned shareholder base.
3	June 18, 2027	-2.0%	26.31	May's FY2028 guidance is the recurring trap: management has twice reset expectations lower at this print. Conservative initial guidance caps enthusiasm even as cash generation normalizes after the receivable build reverses.
4	September 18, 2027	+7.0%	28.15	First monetized AI Search inventory surfaces in the commercial pipeline, and R&D growth decelerates toward revenue growth. Incremental margin recovery restores the adjusted EBITDA bridge investors abandoned during the 2026 investment year.
5	December 18, 2027	+5.0%	29.56	Fed easing begins as energy-driven inflation fades, lowering the discount rate applied to a 6% free-cash-flow yield. Small-cap healthcare IT re-rates modestly; Doximity participates without needing revenue acceleration.
6	March 18, 2028	+4.0%	30.74	Holiday-quarter pharma spend confirms budget reallocation from restricted consumer channels into compliant physician-targeted inventory. Revenue growth returns to high single digits and net revenue retention stabilizes, easing terminal-decay fears.
7	June 18, 2028	-4.0%	29.51	Renewed competitive headlines — enterprise OpenEvidence deployments and free clinician tools from general-purpose AI labs — reignite the terminal-value debate exactly as conservative FY2029 guidance arrives in May.
8	September 18, 2028	+6.0%	31.28	Share count falls below 175 million as the repurchase program is refreshed, mechanically lifting per-share cash flow. A reassuring first-quarter print restores confidence in mid-single-digit revenue durability.
9	December 18, 2028	+4.0%	32.53	New drug-launch cycles across obesity successors and oncology expand the promotional pool. Doximity's point-of-care modules capture incremental budget, lifting December-quarter growth toward double digits for the first time since FY2025.
10	March 18, 2029	+3.0%	33.51	Margin normalization becomes visible as adjusted EBITDA margin returns toward the high forties, helped by falling inference cost per query. The market begins rewarding proof that spending was investment rather than erosion.
11	June 18, 2029	+3.0%	34.51	FY2030 guidance reads credible rather than defensive, a tonal change from prior Mays. Continued buybacks at a still-modest multiple keep per-share compounding comfortably ahead of headline revenue growth.
12	September 18, 2029	+4.0%	35.90	Enterprise health-system contracts for scheduling and credentialing diversify revenue beyond pharma advertising. Reduced concentration among top-twenty pharmaceutical customers supports a slightly higher multiple on unchanged cash flows.
13	December 18, 2029	+3.0%	36.97	Seasonal strength plus a settled policy-rate environment supports mid-cap healthcare technology. The cash balance rebuilds after years of heavy repurchases, restoring management optionality without shareholder dilution.
14	March 18, 2030	+2.0%	37.71	Growth plateaus as the physician network saturates; incremental gains must come from price and new ad formats. The market accepts maturity, paying a stable multiple for reliable free cash flow.
15	June 18, 2030	-3.0%	36.58	A competitive reality check arrives: a well-funded rival's listing or a marquee enterprise win revives share-loss fears. Terminal-value anxiety briefly compresses the multiple despite unchanged near-term earnings and continuing repurchases.
16	September 18, 2030	+5.0%	38.41	Quarterly results disprove the erosion narrative again, with workflow engagement metrics holding firm. Repurchases resume at scale after authorization refresh, and the shrinking float amplifies each incremental dollar of earnings.
17	December 18, 2030	+3.0%	39.56	Budget season confirms the professional channel's structural share gain following consumer-advertising restrictions. Doximity converts compliance and verified audience into durable pricing power on premium point-of-care inventory.
18	March 18, 2031	+2.0%	40.35	Maturity pricing prevails: low-single-digit revenue growth, high-forties EBITDA margins and steady buybacks produce measured appreciation. Macro conditions are neutral, with policy rates settled and healthcare technology near historical average multiples.
19	June 18, 2031	+3.0%	41.56	A dividend initiation or enlarged authorization signals capital-return discipline as the founder-controlled board acknowledges lower reinvestment needs. Per-share cash flow, not revenue, remains the engine of shareholder returns.
20	September 18, 2031	+3.0%	42.81	The five-year arithmetic closes: roughly a third of the float retired, modest revenue growth and a mid-teens EBITDA multiple. Returns came from compounding ownership rather than any narrative re-rating.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Doximity Soars After Q1 Revenue Tops Guidance; Raises FY2027 Viewrttnews.com
[2]Doximity posts Q1 revenue of $156.6M, profit down | DOCS 8-K Filingstocktitan.net
[3]DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Upfinance.yahoo.com
[4]Doximity Inc (DOCS) (Q1 2027) Earnings Call Highlights: AI Leadership Drives Revenue Beat and Raises Full-Year Guidancegurufocus.com
[5]Doximity - Doximity Announces Fiscal 2027 First Quarter Financial Resultsinvestors.doximity.com
[6]Why Doximity Stock Plummeted Todayfinance.yahoo.com
[7]Doximity Sinks 24% As AI Push Fails To Ease Growth Fears - Doximity (NYSE:DOCS) - Benzingabenzinga.com
[8]Doximity, Inc. - Form 8-K - FY2026sec.gov
[9]Doximity, Inc. - Form 8-K - FY2026sec.gov
[10]Doximity, Inc. - Form 8-K - FY2026sec.gov
[11]Doximity’s AI Investment Year Has Arrived: Is Doximity Stock Undervalued at $20 or Nottikr.com
[12]Doximity Names Interim CFO and Announces New Buyback - TipRanks.comtipranks.com
[13]Doximity, Inc. - Form 10-Q - FY2026sec.gov
[14]Open Evidence AI Review 2026: Features and Alternatives | Fastiofast.io
[15]OpenEvidence revenue, valuation & funding | Sacrasacra.com
[16]OpenEvidence vs Doximity | Sacrasacra.com
[17]OpenEvidence Valuation 2026: $12B Round, 40% of US Doctors, and Why It Moved to Miamivalueaddvc.com
[18]Doximity Stock Down 40% in 2026: Is the Selloff Building a Multi-Year Entry Opportunity? | TIKR.comtikr.com
[19]OpenEvidence vs UpToDate vs DoxGPT: The Clinical AI War of 2026iatrox.com
[20]OpenEvidence vs Doximity Ask (2026): Full Comparisonevidencemd.ai
[21]2026 forecast: Pharma ad dollars will continue shifting away from traditional TVfiercepharma.com
[22]pharmaceutical marketing - DTC Perspectivesdtcperspectives.com
[23]Beyond the Commercial Break: Pharma’s Digital Pivot in 2026 - PharmaLeaderspharmaleaders.com
[24]CSRxP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS - CSRxPcsrxp.org
[25]Prescription Drug Marketing Is Changing. The Bigger Question Is Whether Pharma Marketers Are Changing With Itworldofdtcmarketing.com
[26]4As Health Earned Media (8-5-26 update) – 4As Health4ashealth.org

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Michael Burry — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.